Thrombotic Microangiopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thrombotic Microangiopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Thrombotic Microangiopathy is a life-threatening group of hematological diseases characterized by hemolytic anemia (destruction of red blood cells), thrombocytopenia, and microthrombi leading to ischemic tissue injury. In severe cases, TMA leads to kidney injury. Mutations in the ADAMTS13 gene and atypical hemolytic uremic syndrome cause TMA. It can also be caused by infectious diseases, blood-borne diseases, drug-induced etc. Complete blood count to analyze the levels of platelet, RBC, macrophages, and other tests for differential diagnosis. plasma exchange is the primary therapeutic option in which plasma (water and protein portion of blood) is removed from the body and replaced with fresh donor plasma followed by symptomatic care with corticosteroids, antibiotics etc.
The Thrombotic Microangiopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Thrombotic Microangiopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombotic Microangiopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thrombotic Microangiopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thrombotic Microangiopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thrombotic Microangiopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thrombotic Microangiopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akari Therapeutics PlcAlexion Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Createrna Science and Technology Co Ltd
Kira Pharmaceuticals
NovelMed Therapeutics Inc
Omeros Corp
Takeda Pharmaceutical Co Ltd
Transcenta Holding Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Thrombotic Microangiopathy reports